StockData
Contineum Therapeutics, Inc. logo

Contineum Therapeutics, Inc. (CTNM) stock

CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$9.86+0.08 (+0.82%)

Close on Nov 13, 2026Market cap $370.94MP/E –Yield –

Earnings

Contineum Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 4, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.49
-$0.45 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Contineum Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 4, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026after the close––-$0.49Release
Q2 FY2026ended Jun 30, 2026Jul 30, 2026after the close–––Release
Q1 FY2026ended Mar 31, 2026May 5, 2026after the close–––Release
Q4 FY2025ended Dec 31, 2025Mar 5, 2026after the close––-$0.49Release
Q3 FY2025ended Sep 30, 2025Oct 30, 2025after the close––-$0.45Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025after the close––-$0.62Release
Q1 FY2025ended Mar 31, 2025May 14, 2025after the close––-$0.62Release
Q4 FY2024ended Dec 31, 2024Mar 6, 2025after the close––-$0.56Release
Q3 FY2024ended Sep 30, 2024Nov 6, 2024after the close–––Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024after the close––-$0.39Release
Q1 FY2024ended Mar 31, 2024May 16, 2024after the close––-$3.55Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Contineum Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Contineum Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Contineum Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. CONTINEUM THERAPEUTICS REPORTS THIRD-QUARTER 2026 FINANCIAL RESULTS
    Results
  2. CONTINEUM THERAPEUTICS REPORTS PHASE 2 RESULTS FOR JNJ-5120/PIPE-307 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
    News
  3. CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES
    Results
  4. Corporate Overview JULY 2026 Exhibit 99.1
    Update
  5. CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES
    Results
  6. CONTINEUM THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM ITS EXPLORATORY PIPE-791 PHASE 1B TRIAL IN CHRONIC PAIN
    Update
  7. PIPE-791 Phase 1b Chronic Pain Trial Topline Data Supplemental Information April 30, 2026 Exhibit 99.2
    Update
  8. CONTINEUM THERAPEUTICS REPORTS FOURTH-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES
    Results
  9. Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
    News
  10. Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
    News
  11. CONTINEUM THERAPEUTICS REPORTS TOPLINE DATA FROM ITS PHASE 2 PIPE-307 VISTA TRIAL FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS)
    News
  12. CONTINEUM THERAPEUTICS REPORTS THIRD-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES
    Results
  13. CONTINEUM THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM PHASE 1B POSITRON EMISSION TOMOGRAPHY (PET) TRIAL OF PIPE-791
    Update
  14. 8-K exhibit EX-99.2
    Update
  15. CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2025 FINANCIAL RESULTS; UPDATES KEY CLINICAL DEVELOPMENT MILESTONES
    Results

See a number that looks wrong?